Warrants exercised
ChroMedX receives $226,200 from warrant exercise
2017-12-13 16:24 ET - News Release
Mr. Gerard Edwards reports
CHROMEDX ANNOUNCES EXERCISE OF WARRANTS
Since November, 2017, investors have exercised warrants to acquire 1,031,000 new common shares of ChroMedX Corp. as of Dec. 12, 2017.
The total consideration received was $226,200. The warrant shares will rank pari passu in all respects with the existing common shares of the company.
Recent news
The company most recently announced the appointment of Dr. Richard Janeczko to its board of directors.
Dr. Janeczko is a veteran of the medical diagnostics industry with more than 25 years of experience in development and commercial transaction of novel technology and device companies. He has worked in multiple clinical areas, including critical care medicine, oncology and infectious disease, driving value-based strategies for companies bringing advanced diagnostics into medical practice. Dr. Janeczko is also the chief executive officer of DxEconomix Inc., a diagnostic marketing firm headquartered in Glendale, Calif.
About ChroMedX Corp.
ChroMedX is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the company's issued and pending patents dealing with blood collection, analysis and plasma/serum processing.
We seek Safe Harbor.